Large-scale testing (Phase 3)Study completedNCT05803421
What this trial is testing
Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Who this might be right for
Type 2 DiabetesObesityOverweight or Obesity+3 more
Eli Lilly and Company 2,749